In mice, inhibiting PDE4 with roflumilast kept semaglutide‑induced cAMP levels high in the area postrema, potentially extending the drug’s weight‑loss effect.
Neuronal cAMP Dynamics
Fluorescence imaging of living brain slices revealed that semaglutide triggers a continuum of cAMP responses across GLP‑1R‑expressing neurons. Some cells sustained elevated cAMP for hours, while others showed only transient spikes, likely due to rapid receptor internalization.
Sustained responders were the key to weight loss, as the researchers linked persistent cAMP elevation to appetite suppression. Variability among neurons may explain why patients experience different degrees of weight loss and why the effect plateaus over time.
PDE4 Inhibition as a Potentiator
By administering roflumilast, a PDE4 inhibitor, the team shifted the balance toward sustained cAMP. Roflumilast prevented cAMP degradation, keeping the signal alive in more neurons.
Pharmacological manipulation reduced the need for repeated semaglutide dosing in mice, suggesting a strategy to prolong efficacy in humans. Approach could also help overcome the plateau that limits long‑term weight loss for many patients.
Future Directions and Clinical Implications
Current imaging techniques capture intracellular events over hours; the authors plan to extend observations to days and weeks using advanced in vivo methods. If sustained cAMP signaling translates to human therapy, combining GLP‑1 agonists with PDE4 inhibitors could lower dosing frequency and improve adherence.
Next step will involve clinical trials to test safety and efficacy of such combination regimens. By mapping the intracellular choreography of semaglutide, NIH researchers have uncovered a tangible lever—PDE4 inhibition—that may make GLP‑1 therapy more durable and patient‑friendly.
Source: NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Domain: nih.gov
Comments load interactively on the live page.